SCHEMBL5018733

SCHEMBL5018733

CC(C)Cc1ccc(F)c(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.44
GABRB2 P47870 1/20 0.44
CYP2C9 P11712 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 2/20 0.44
PARP1 P09874 2/20 0.37
CHRM1 P11229 1/20 0.36
PDE4A P27815 1/20 0.36
PTGS1 P23219 3/20 0.35
PTGS2 P35354 3/20 0.35
LMNA P02545 2/20 0.35
AKR1C3 P42330 2/20 0.35
CXCR1 P25024 2/20 0.35
CXCR2 P25025 2/20 0.35
ALB P02768 1/20 0.35
ESR1 P03372 1/20 0.35
ALOX5 P09917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8252707 0.84 GABRA1 (0.44) GABRA1GABRB2CYP2C9CYP1A2CYP2D6
SCHEMBL9176216 0.81 GABRA1 (0.48) GABRA1GABRB2CYP2C9CYP1A2CYP2D6
SCHEMBL2623873 0.81 GABRA1 (0.48) GABRA1GABRB2CYP2C9CYP1A2CYP2D6
SCHEMBL27847285 0.80 TSHR (0.47) CYP2C9CYP1A2CYP2D6CYP2C19NPSR1
SCHEMBL10202985 0.78 GRIN2D (0.44) CYP2C9CYP1A2CYP2D6CYP2C19NPSR1
SCHEMBL8252056 0.78 GABRA1 (0.46) GABRA1GABRB2
SCHEMBL27520994 0.78 GABRA1 (0.46) GABRA1GABRB2CYP2C9CYP1A2CYP2D6
SCHEMBL2858438 0.77 CYP1A2 (0.51) CYP2C9CYP1A2CYP2D6CYP2C19NPSR1
SCHEMBL1000955 0.77 MEN1 (0.41) CYP2C9CYP1A2CYP2D6CYP2C19NPSR1
SCHEMBL17275579 0.77 CYP1A2 (0.40) CYP2C9CYP1A2CYP2D6CYP2C19NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178490-B2 Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof REMPEX PHARMACEUTICALS, INC. (US) 2012-05-15 US disclosed
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed
US-20080318957-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF ABCB11, ABCB1, SLC47A1 GABRA1 2667/4885GABRB2 1652/4885CYP2C9 3081/4885
US-20080318957-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF ABCB11, ABCB1, SLC47A1 GABRA1 2667/4885GABRB2 1652/4885CYP2C9 3081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.